Category : Seaking Alpha

Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

8 hours ago
Vulnerable counties in U.S. housing market cluster around East Coast, Chicago

8 hours ago
CELLCOM ISRAEL LTD. ANNOUNCES EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

10 hours ago
Activist fund Trian is said to take stake in Unilever - FT

11 hours ago
ALERT: Investors in NRx Pharmaceuticals, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPW

14 hours ago